Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Discover OncologyOpen Access

Integrative advances in biomarker-driven prostate cancer management from genomic discovery to precision oncology

View Full Paper
Ask AI
Bookmark
Share

Authors

PRPriyanka RameshLSLeena ShreeABAlex Stanley Balraj

Discussion

Loading...

Member takes

Overview

This review examines biomarker advances in prostate cancer management, indicating a trend towards precision oncology.

Key Points

  • This review aims to consolidate advances in prostate cancer biomarkers and their implications for precision oncology.
  • Review of recent advances in genetic, proteomic, liquid biopsy, and imaging approaches for prostate cancer.
  • Discussion of established and emerging biomarkers including ctDNA, PCA3, and imaging tools.
  • Integration of artificial intelligence in multiparametric MRI analysis to enhance detection and staging.
  • Genetic mutations provide insights for therapy selection and disease prognosis.
  • Liquid biopsy markers, such as ctDNA and PCA3, enable minimally invasive risk stratification.
  • Integration of biomarker-driven strategies into clinical practice supports improved patient outcomes.

Cite This Study

Ramesh et al. (2026) studied this question.

synapsesocial.com/papers/6a192c67fab5b468c44154d2https://doi.org/10.1007/s12672-026-05311-7
View Full Paper
Ask AI
Bookmark
Share